These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 3923595)
21. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination]. Wichmann O; Ultsch B Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088 [TBL] [Abstract][Full Text] [Related]
22. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases. Thompson KM; Badizadegan ND Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947 [TBL] [Abstract][Full Text] [Related]
23. Rubella: the challenge of its control. Horstmann DM J Infect Dis; 1971 Jun; 123(6):640-54. PubMed ID: 4938949 [No Abstract] [Full Text] [Related]
24. Prevention of the congenital rubella syndrome: the Israeli experience. Fogel A; Gerichter CB; Goldblum N Prog Clin Biol Res; 1985; 163B():327-32. PubMed ID: 3983160 [No Abstract] [Full Text] [Related]
25. Follow-up on rubella vaccinations and experience with subclinical reinfection. Farquhar JD J Pediatr; 1972 Sep; 81(3):460-5. PubMed ID: 5065683 [No Abstract] [Full Text] [Related]
28. Systematic Review of Health Economic Analyses of Measles and Rubella Immunization Interventions. Thompson KM; Odahowski CL Risk Anal; 2016 Jul; 36(7):1297-314. PubMed ID: 25545778 [TBL] [Abstract][Full Text] [Related]
29. Congenital rubella syndrome: continuing challenge of a preventable infection. Rhodes AJ Can Med Assoc J; 1977 Mar; 116(5):463-6. PubMed ID: 837306 [No Abstract] [Full Text] [Related]
30. Rubella: facts and questions. Shanholtz MI Va Med Mon (1918); 1969 Jun; 96(6):341-2. PubMed ID: 5816649 [No Abstract] [Full Text] [Related]
31. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec; 2011 Jul; 86(29):301-16. PubMed ID: 21766537 [No Abstract] [Full Text] [Related]
32. Prevention of congenital rubella infection. Menser MA Med J Aust; 1984 May; 140(11):636-8. PubMed ID: 6425618 [No Abstract] [Full Text] [Related]
33. Leads from the MMWR. Rubella prevention. JAMA; 1984 Jul; 252(2):192-5, 199-200. PubMed ID: 6727016 [No Abstract] [Full Text] [Related]
34. Rubella: the U. K. experience. Dudgeon JA Dev Biol Stand; 1979; 43():327-38. PubMed ID: 520679 [No Abstract] [Full Text] [Related]
35. Rubella antibody titers in vaccinated and nonvaccinated women and results of vaccination during pregnancy. Enders G Rev Infect Dis; 1985; 7 Suppl 1():S103-7. PubMed ID: 4001718 [TBL] [Abstract][Full Text] [Related]
36. [Comparison of cost and benefits of each model for rubella immunization in Japan]. Terada K; Niizuma T; Daimon Y; Kataoka N Kansenshogaku Zasshi; 2000 Dec; 74(12):1012-7. PubMed ID: 11193552 [TBL] [Abstract][Full Text] [Related]
37. [Prevention of congenital malformations caused by rubella]. Giuliani G Minerva Med; 1971 May; 62(40 Suppl):9-12. PubMed ID: 5555951 [No Abstract] [Full Text] [Related]
38. A benefit-cost analysis of two-dose measles immunization in Canada. Pelletier L; Chung P; Duclos P; Manga P; Scott J Vaccine; 1998; 16(9-10):989-96. PubMed ID: 9682349 [TBL] [Abstract][Full Text] [Related]
39. Rubella: the U. S. experience. Hinman AR; Preblud SR; Brandling-Bennett AD Dev Biol Stand; 1979; 43():315-26. PubMed ID: 520678 [No Abstract] [Full Text] [Related]
40. Cost-benefit analysis of routine mumps and rubella vaccination for Israeli infants. Berger SA; Ginsberg GM; Slater PE Isr J Med Sci; 1990 Feb; 26(2):74-80. PubMed ID: 2108102 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]